Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | CTSG | P08311 | 4/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.50 |
| ▸ | CMA1 | P23946 | 4/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003142 | 1.00 | PRSS1 (0.50) | PRSS1CTSGCTRB1CMA1NAAA | |
| SCHEMBL10147876 | 0.81 | ABCB1 (0.48) | PRSS1CTSGCTRB1CMA1POLB | |
| SCHEMBL19946423 | 0.81 | ABCB1 (0.48) | PRSS1CTSGCTRB1CMA1POLB | |
| SCHEMBL10147831 | 0.81 | ABCB1 (0.48) | PRSS1CTSGCTRB1CMA1POLB | |
| SCHEMBL4629693 | 0.80 | ABCB1 (0.58) | CYP3A4 | |
| SCHEMBL165545 | 0.80 | L3MBTL1 (0.48) | PRSS1CTSGCTRB1CMA1NAAA | |
| SCHEMBL13983605 | 0.77 | ABCB1 (0.48) | PRSS1CTSGCTRB1CMA1POLB | |
| SCHEMBL4630345 | 0.77 | ABCB1 (0.44) | CYP3A4 | |
| SCHEMBL668626 | 0.75 | ABCB1 (0.60) | CYP3A4 | |
| SCHEMBL9877218 | 0.74 | POLB (0.58) | POLBCYP3A4CYP2C9TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272986-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9272986-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | NR2E3, NR2C2, NR5A2 | PRSS1 2712/4885CTSG 4623/4885CTRB1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.